184 related articles for article (PubMed ID: 36316485)
21. The future of interleukin-2: enhancing therapeutic anticancer vaccines.
Overwijk WW; Theoret MR; Restifo NP
Cancer J Sci Am; 2000 Feb; 6 Suppl 1(Suppl 1):S76-80. PubMed ID: 10685664
[TBL] [Abstract][Full Text] [Related]
22. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Hu Z; Xia J; Fan W; Wargo J; Yang YG
Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
[TBL] [Abstract][Full Text] [Related]
23. Targeted antibody and cytokine cancer immunotherapies through collagen affinity.
Ishihara J; Ishihara A; Sasaki K; Lee SS; Williford JM; Yasui M; Abe H; Potin L; Hosseinchi P; Fukunaga K; Raczy MM; Gray LT; Mansurov A; Katsumata K; Fukayama M; Kron SJ; Swartz MA; Hubbell JA
Sci Transl Med; 2019 Apr; 11(487):. PubMed ID: 30971453
[TBL] [Abstract][Full Text] [Related]
24. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
25. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
Lo AS; Ma Q; Liu DL; Junghans RP
Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
[TBL] [Abstract][Full Text] [Related]
26. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
27. Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy.
Kim J; Kang S; Kim KW; Heo MG; Park DI; Lee JH; Lim NJ; Min DH; Won C
Biomaterials; 2022 Jan; 280():121257. PubMed ID: 34839122
[TBL] [Abstract][Full Text] [Related]
28. IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients.
Vuletić A; Jovanić I; Jurišić V; Milovanović Z; Nikolić S; Spurnić I; Konjević G
Pathol Oncol Res; 2020 Jan; 26(1):223-231. PubMed ID: 29948616
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
30. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.
Moynihan KD; Opel CF; Szeto GL; Tzeng A; Zhu EF; Engreitz JM; Williams RT; Rakhra K; Zhang MH; Rothschilds AM; Kumari S; Kelly RL; Kwan BH; Abraham W; Hu K; Mehta NK; Kauke MJ; Suh H; Cochran JR; Lauffenburger DA; Wittrup KD; Irvine DJ
Nat Med; 2016 Dec; 22(12):1402-1410. PubMed ID: 27775706
[TBL] [Abstract][Full Text] [Related]
31. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
[TBL] [Abstract][Full Text] [Related]
32. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
[TBL] [Abstract][Full Text] [Related]
33. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.
Tietze JK; Wilkins DE; Sckisel GD; Bouchlaka MN; Alderson KL; Weiss JM; Ames E; Bruhn KW; Craft N; Wiltrout RH; Longo DL; Lanier LL; Blazar BR; Redelman D; Murphy WJ
Blood; 2012 Mar; 119(13):3073-83. PubMed ID: 22251483
[TBL] [Abstract][Full Text] [Related]
34. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8
Rolig AS; Rose DC; McGee GH; Rubas W; Kivimäe S; Redmond WL
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444059
[TBL] [Abstract][Full Text] [Related]
35. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
[TBL] [Abstract][Full Text] [Related]
36. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
Kermer V; Baum V; Hornig N; Kontermann RE; Müller D
Mol Cancer Ther; 2012 Jun; 11(6):1279-88. PubMed ID: 22491823
[TBL] [Abstract][Full Text] [Related]
37. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.
Tähtinen S; Kaikkonen S; Merisalo-Soikkeli M; Grönberg-Vähä-Koskela S; Kanerva A; Parviainen S; Vähä-Koskela M; Hemminki A
PLoS One; 2015; 10(6):e0131242. PubMed ID: 26107883
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 21 treatment in a murine model as a novel potential cytokine immunotherapy for colon cancer.
Chen C; Liu X; Ren Y
Adv Clin Exp Med; 2018 May; 27(5):583-589. PubMed ID: 29616746
[TBL] [Abstract][Full Text] [Related]
39. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
40. Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer.
Pan Y; Hao Y; Han H; Chen T; Ding H; Labbe KE; Shum E; Guidry K; Hu H; Sherman F; Geng K; Stephens J; Chafitz A; Tang S; Huang HY; Peng C; Almonte C; Lopes JE; Losey HC; Winquist RJ; Velcheti V; Zhang H; Wong KK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36472839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]